来凯医药-B(02105):LAE103的I期单剂量递增研究完成首例受试者给药

智通财经网
Dec 31, 2025

智通财经APP讯,来凯医药-B(02105)发布公告,本集团已在澳大利亚启动LAE103(一种自研的ActRIIB单克隆抗体)的I期单剂量递增研究(SAD研究)的受试者入组工作。截至本公告日,首位受试者已完成给药。

该SAD研究为一项随机、双盲、安慰剂对照研究,旨在评估LAE103(皮下注射)在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项SAD研究的顶线数据。

本集团致力将此精准疗法引入心血管与代谢疾病中存在重大未满足医疗需求的领域,例如肥胖症、肌少症及心衰等。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10